Eli Lilly and Company today announced that Maura Dickler, M.D., a prestigious breast cancer researcher, will join Lilly Oncology as Vice President of Late Phase Development on May 7, 2018.
Dr. Dickler is currently the Section Head, Endocrine Therapy Clinical Research Program at Memorial Sloan Kettering Cancer Center (MSKCC). She concurrently serves as Associate Member, Breast Medicine Service, Department of Medicine, MSKCC and Associate Professor of Medicine, Weill Cornell Medical College, NY. She will report to Levi Garraway, M.D., Ph.D., Senior Vice President, Global Development & Medical Affairs of Lilly Oncology.
“Dr. Dickler is an internationally recognized oncology leader with drug development expertise spanning a wide range of therapeutic modalities,” said Garraway. “Moreover, she is an exceptionally gifted clinician for whom patients are at the center of everything she does. We are thrilled to have Dr. Dickler join us at Lilly.”
About Maura Dickler, M.D.
Dr. Dickler graduated from The University of Chicago’s Pritzker School of Medicine and completed her fellowship at MSKCC. She is a clinical researcher on the Breast Medicine Service at MSKCC, with a research program focused on developing new therapeutic strategies for the treatment of women with hormone-receptor positive (HR+) breast cancer. She has led clinical trials investigating therapeutic agents targeting several growth factor receptor-signaling pathways important in breast cancer, including the epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor receptor (VEGFR), phosphoinositide 3-kinase (PI3K) and the estrogen receptor pathway. She has also investigated cyclin-dependent kinase 4 & 6 (CDK4 & 6) inhibitors targeting the cell cycle.
Dr. Dickler’s research and clinical accomplishments have led to numerous publications and she has served on various committees including the Breast Committee of The Alliance for Clinical Trials in Oncology. She has received honors for her clinical care, including New York Magazine’s Best Doctors, Medical Oncology in 2015, 2016 and 2017; Castle Connolly America’s Top Doctors; and Castle Connolly Exceptional Women in Medicine in 2017.
Source: Eli Lilly and Company
Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.
Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.
Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.